Man Group PLC Oramed Pharmaceuticals Inc. Transaction History

Man Group PLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$5.88 - $12.03 $92,016 - $188,257	-15,649 Reduced 22.05%	55,316 $665,000
Q3 2022 Nov 14, 2022	SELL	$4.6 - $9.91 $72,270 - $155,696	-15,711 Reduced 18.13%	70,965 $460,000
Q2 2022 Aug 15, 2022	BUY	$3.72 - $9.0 $264,402 - $639,684	71,076 Added 455.62%	86,676 $397,000
Q1 2022 May 16, 2022	BUY	$8.19 - $13.89 $127,763 - $216,684	15,600 New	15,600 $135,000
Q4 2021 Feb 14, 2022	SELL	$12.98 - $29.75 $483,959 - $1.11 Million	-37,285 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$12.13 - $23.82 $284,873 - $559,412	23,485 Added 170.18%	37,285 $820,000
Q2 2021 Aug 16, 2021	BUY	$8.34 - $14.59 $115,092 - $201,342	13,800 New	13,800 $185,000

7.4M

2.1K

Ticker ORMP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,827,100
Market Cap $90.9M
Description
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for th...

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

Stay updated on Man Group PLC with notifications on news.